Novavax monovalent COVID-19 booster authorized for adults
The Food and Drug Administration yesterday authorized, and the Centers for Disease Control and Prevention recommended, the Novavax COVID-19 vaccine as a first booster dose for adults who would not otherwise receive one. Unlike the bivalent mRNA boosters made by Pfizer and Moderna, the Novavax booster has not been updated to protect against more recent SARS-CoV-2 variants but provides an alternative for adults who cannot or prefer not to receive an mRNA booster.
Related News Articles
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…